Clinical Trial Update: NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial of NXP800 for advanced or metastatic cholangiocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Hilar Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• NXP800 (NXP800)

Snippet

Sponsor: Mayo Clinic | Conditions: Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 1 | Status: TERMINATED